This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer Ibrance sNDA Accepted by FDA under Priority Review
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.
Clovis Scales 52-Week High on Early FDA Nod for Rubraca
by Zacks Equity Research
Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.
Ionis (IONS) Receives Milestone Payment from AstraZeneca
by Zacks Equity Research
Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.
Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe
by Zacks Equity Research
Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.
Biogen Presents Positive Early Data from Alzheimer's Study
by Zacks Equity Research
Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
Lilly/AstraZeneca Expand Alzheimer Disease Collaboration
by Zacks Equity Research
Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs
by Arpita Dutt
Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.
AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting
by Zacks Equity Research
AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.
Top Research Reports for Cisco, Merck & MasterCard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including MasterCard (MA), Merck (MRK) and Cisco (CSCO).
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
by Arpita Dutt
This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.
Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
by Eric Dutram
In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.
Argument for Interest Rate Hike "Quite Strong"
by Mark Vickery
Fed Vice Chair Stanley Fischer said he is optimistic a rate hike would be manageable abroad, and that a stronger U.S. economy should help other countries.
Is Brexit a Buying Opportunity?
by Tracey Ryniec
Value investors should keep an eye on what is going on in Great Britain right now.
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
by Mark Vickery
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
Low PE Stocks For This Market
by Brian Bolan
A look at four stocks with low PE's and earnings estimate revisions that are among the best over the last four weeks.
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.